What question did this study set out to answer?

To construct and evaluate a dual-targeted nanoparticle system combining chemotherapy and immunotherapy to overcome immunosuppression in the tumor microenvironment.

November 15, 2024Small

Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment

View Full Paper

Ask AI

Bookmark

Authors

ZGZishuo Guo HZHaocheng Zheng TWTieshan Wang

Discussion

Member takes

Overview

Preclinical study demonstrates synergistic tumor suppression and immune activation in tumor-bearing mice, highlighting a dual-action nanodrug delivery platform.

Key Points

To construct and evaluate a dual-targeted nanoparticle system combining chemotherapy and immunotherapy to overcome immunosuppression in the tumor microenvironment.
Engineered tumor-targeted PD-L1@Cur-NPs to induce cancer cell apoptosis and T-cell-targeted PD-1@AS-NPs to stimulate host immune responses.
Evaluated therapeutic efficacy, tumor volume reduction, and immune cell profiling in C57BL/6 tumor-bearing mouse models.
Combination treatment with both nanoparticles significantly reduced tumor volumes in C57BL/6 mice compared to controls.
Intratumoral infiltration of CD8+ and CD4+ T cells significantly increased, alongside a significant decrease in immunosuppressive regulatory T cells.
Spleen populations of memory T cells and memory effector T cells increased significantly, confirming sustained activation of systemic antitumor immunity.

Cite This Study

Guo et al. (2024) studied this question.

synapsesocial.com/papers/6ab1fbfea5616fbbb8241d25 https://doi.org/10.1002/smll.202405752

View Full Paper

Ask AI

Bookmark

November 15, 2024Small

Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment

View Full Paper

Ask AI

Bookmark

Authors

ZGZishuo Guo HZHaocheng Zheng TWTieshan Wang

Discussion

Member takes

Overview

Preclinical study demonstrates synergistic tumor suppression and immune activation in tumor-bearing mice, highlighting a dual-action nanodrug delivery platform.

Key Points

To construct and evaluate a dual-targeted nanoparticle system combining chemotherapy and immunotherapy to overcome immunosuppression in the tumor microenvironment.
Engineered tumor-targeted PD-L1@Cur-NPs to induce cancer cell apoptosis and T-cell-targeted PD-1@AS-NPs to stimulate host immune responses.
Evaluated therapeutic efficacy, tumor volume reduction, and immune cell profiling in C57BL/6 tumor-bearing mouse models.
Combination treatment with both nanoparticles significantly reduced tumor volumes in C57BL/6 mice compared to controls.
Intratumoral infiltration of CD8+ and CD4+ T cells significantly increased, alongside a significant decrease in immunosuppressive regulatory T cells.
Spleen populations of memory T cells and memory effector T cells increased significantly, confirming sustained activation of systemic antitumor immunity.

Cite This Study

Guo et al. (2024) studied this question.

synapsesocial.com/papers/6ab1fbfea5616fbbb8241d25 https://doi.org/10.1002/smll.202405752

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark